Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

SciTech Development Announces the Closing of Oversubscribed $5.5 Million Funding Round to Continue Cancer Clinical Trials

Summary by The Big Spring Herald
Investor confidence is fueled by remarkable interim clinical trial results for its drug, ST-001 nanoFenretinide™, showing 100% disease control at higher dose levels.

4 Articles

The Big Spring HeraldThe Big Spring Herald
+3 Reposted by 3 other sources
Center

SciTech Development Announces the Closing of Oversubscribed $5.5 Million Funding Round to Continue Cancer Clinical Trials

Investor confidence is fueled by remarkable interim clinical trial results for its drug, ST-001 nanoFenretinide™, showing 100% disease control at higher dose levels.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Big Spring Herald broke the news in on Wednesday, September 24, 2025.
Sources are mostly out of (0)

Similar News Topics

Stoughton, Massachusetts icon

Stoughton, Massachusetts

News
For You
SearchBlindspotLocal